Back to Search
ELEFTHERIOS P MAMOUNAS MD
MD
Surgery Physician
NPI: 1174580492IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
35072102M(OH)ME114413(FL)
Surgical Oncology Physician
Surgery — Surgical Oncology
Code: 2086X0206X
ME114413(FL)
Education
OTHER
Class of 1983
Research & Publications (20)
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
PMID 19349544·J Clin Oncol·2009
2-rct
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
PMID 18302020·Breast Cancer Res Treat·2009
4-observational
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
PMID 18830816·Breast Cancer Res Treat·2009
8-other
Age and lymph node status in breast cancer: not a straightforward relationship.
PMID 19451421·J Clin Oncol·2009
8-other
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer.
PMID 18612150·J Clin Oncol·2008
4-observational
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
PMID 18258986·J Clin Oncol·2008
4-observational
Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.
PMID 18347556·Clin Adv Hematol Oncol·2008
8-other
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.
PMID 18784962·Ann Surg Oncol·2008
2-rct
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
PMID 18332472·J Clin Oncol·2008
4-observational
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
PMID 18929150·Semin Oncol·2008
6-review
Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling.
PMID 18516819·Clin Adv Hematol Oncol·2008
5-case
Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
PMID 18196346·Ann Surg Oncol·2008
6-review
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
PMID 18258988·J Clin Oncol·2008
6-review
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
PMID 17851130·Lancet Oncol·2007
3-trial
Is sentinel node biopsy necessary in conservatively treated DCIS?
PMID 17534687·Ann Surg Oncol·2007
8-other
Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project.
PMID 17498527·Surg Clin North Am·2007
8-other
Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors.
PMID 17826050·Am J Surg·2007
4-observational
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
PMID 16648502·J Clin Oncol·2006
2-rct
Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience.
PMID 17060221·Clin Trials·2006
8-other
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
PMID 17239269·Clin Breast Cancer·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2501 N ORANGE AVE STE 389
ORLANDO, FL 32804 - Phone
- (407) 303-5214
Quick Facts
- NPI
- 1174580492
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 43
- Publications
- 20
Are you this provider?
Claim Your Profile